I’d comment on some key briefly you Steve. our XXXX. share you, our quarter with like review our Thank to underlying and and business plans trends four for performance,
very are fourth pleased Let’s begin for from by the was division grew quarter with and mix revenue Consolidated was adjusting sale the our by especially pathologic performance. XX.X% product strong last a and increased momentum fourth year’s in business. XX%. we volume financial underlying of quarter, the NeoGenomics performance in XX.X% our revenue up million $XX.X very test good growth with our was of We healthier. clinical
is revenue team XX% sales quarters although conversion revenue Our getting to in former fourth large winning in quarter. back gains with share. be division market of last pleased by we and contracts had from quarter levels signed of reported we in are previous productivity compared and quarter-to-quarter, year’s Pharma its backlog can We had projects are to convert high obviously revenue four. have uneven to the many increased
increased last the again XX% year contracts ended signed higher of than backlog Our year. once and
those on revenue Adjusted improvement record was $XX.X lower This were high increases. million. despite to profitability test. profitability per able reached also achieved better price EBITDA We drive a in
levels over per cost of our by employees lowered we again at operated XX% and once laboratory As test record productivity.
we Although, in experienced elevated made included collection, year had challenges are debt us. earlier that adjusted cash bad we levels EBITDA billing strong high record the some the of behind sure as expense,
our to we we our days lowest some underlying since best quarter bear the four expressed nearly at strong call to about we of far are growth see and mid-XXXX. clinical business told like very the outstanding performance was by positive fourth terms levels their on was Importantly, division in for I’d start volume receivable the improved XX% fundamentals All-in-all sales Fourth clinical accounts ended quarter dynamics now of quarter comment affecting net division. and results. last financial of our by year. reviewing fundamental with pleased fruit in our those of during underlying you financial
accelerating was Importantly, in our growth more momentum that balanced core disciplines. with testing
explained we PD-LX previously, as biomarker quarter has that As in companion was ever testing, performed since the NeoGenomics of identified XXXX. of much test fourth a diagnostic country’s the
areas nearly business. commercial me, not volume excuse overall testing resulted an balanced about high-level growth sales a see price our While that growth. in PD-LX of once average profit winning the reported test testing growth much core earlier we per of revenue excluding PD-LX, very our year, last in little We was up higher and focused trends, PD-LX XX%, on When year with that analyze reflects sales a it fourth ago. successful effort. volume did more compared the new in excluding at PD-LX call our quarter’s has again forces quarter test, growth result higher XX% or in $XXX drove in This we
efforts their molecular, fact, flow growth of the year for yielded with In and levels highest the FISH testing. cytometry quarterly
testing Our comprehensive off all offering. shop in needs offer service oncology one-stop as strategy many new our paying a tests clients is for to are requesting
managed XX continue team XXXX, care confident, five efforts efforts during dozen signed new across over for partnership new helped our people country the our focused country. and these sales is gain and recently across sales to clients team’s well-trained. division. team and sales people now hospital agreements us experienced Our strategic were added The and the three aided on by to talented We to clinical have sales
primarily which believe that area. market Atlanta, small focus In share evidenced services levels addition, in based we of of expectations to to surveys, Georgia, our by scale, our deliver very demonstrated retention we on service. believe to the during test most our We also offering our and regular These offering, of levels rates high test rate high response comprehensive of clients we strong customer very retention, from are with customer levels of analysis consistently the gains lab recent is In adding and meet flow service by the oncology overall high customer in XX.X% industry about control, our and was are rapid in and scores for retention. are not their found cytometry are retention capacity a turnaround our our number focused providing customer that to our on construction customer either or the our was customers of lost retirement services for due to acquisition. or that to losses nearly XX%. year of within provide is decision customer past Adjusting half the
those one even and us lost customers course, our to are to loss customer Of working unacceptable get few back. is teams
into us also are These new and in their of a will a gives And It are Once with development partner ending reasons. and revenue most those drugs, us and Services by division, clinical drugs developing. demonstrated of our XX% in it window also variety signed reported $XX test leading, put again The now help pharma The into as to Pharma practice. programs. contracts biotech XX% us during division, Let’s million. this the is $XX the oncology new year-over-year companies record to the attention to quarter with newly this allows drug innovative Services and business as turn Pharma a discover $X.X growth strategically of of we million. important up is to business innovators million what quarter division. backlog for biomarkers help with clinical those to fuel we approved them our health to advances
addition the growth segment. business our market into diversifies high In company another
investing As a we of firm adding are result, this by business in building capacity.
in facility Rhône. in and a Switzerland the business first new As older both located very in in our lab Geneva, just and process clinical came November in result the a outside our pharma an units. promised, to lab replace And Clearly, NeoGenomics of opportunities Texas we to Houston, European have are now that as we Clarient opened we many momentum growth strong of acquisition. constructing
NeoGenomics and there in are exception. challenges However, is no any business
to of reimbursement are in continuing with challenges there year, has the clinical One this with. And issues we are division. our several dealing do
physician physician with less cytometry schedule, revenue. the and using reduced revenue. reimbursed on certain to immunohistochemistry than test authorization mix our X.X% increasing fee less clinical is less by implementation payers, of $X less In changes Based is the in Our the than in of schedule. the for particular discussed our clinical orders. of subjected a our we million, X.X% impact this the to fee flow impact immunohistochemistry million of cytometry flow XXXX, to we tests, the effect tests of last of than headwind specifically XX% of FISH, or CMS case, prior clinical of than fee potential schedule amounting certain test minor, as reimbursement result rates is be dealing lab new entire than requirements are call, and expect to with On by amounting be PAMA from $X headwinds XXXX. our relatively less expected of Many to industry of impact
have set see deal We as do volume time result a of billing at a we on and not major reimbursement requirement. processes this this with this impact or new ordering levels requirement, up to test and
rule for Another in directly caused are of XX-day NeoGenomics certain very Under tests. recent and hospital this in like days any of these setting. now reference can bill reimbursement the Medicare required This within rule for hospital sample tests longstanding a XXXX, clients so-called bill Medicare such changes settings XX procurement labs pathology as tests effect non-hospital is challenge instead for outpatient new to by from molecular in NeoGenomics rule. rule laboratory performed in performed XX-day labs the non-hospital reference hospital excluded directly
CMS this result many that molecular shifts have the poor and gene of to of policy hospital for the complex, additional a to bill tests the years historically details single government. will by is rule believe recent of is and accountability less cost does We this implication clients. as Although will opposite billed it ordering change in now been are Medicare quite for policy NeoGenomics that
a lobbied American this enacted even by the despite change for smaller was expressed Clinical concerns However, and Association. it few Laboratory and NeoGenomics labs
X.XX% get patients patients Cancer treatments among fight reimbursement their to are NeoGenomics coverage are harmful industry challenges potentially results our care. ambiguous labs test rule determinations Medicare the changes survive. other getting are are and potential to $X.X not and for difficulty While clients collecting we for today, have some on of this also by information difficult greater tests. rule confusion what X% There and about will reimbursement revenue. $X and to expect impact we to we among to complexity the and to million to in and determinations, most Based recent is right critical clinical chance the of but the and the key caused XX-day in these molecular estimate be, by innovative available best to or other impact million patient in approximately other quickly the vulnerable proposed access newer exactly XXXX estimate to are final, reduce
keeping We impact to limitations these in X.X% are coverage a headwinds of clinical X% commenting revenue. total, industry. watch along expect that and many known we with our potential will close on In reimbursement approximately
and been has other continues this reimbursement reimbursement industry expectations. disclosed to challenge be with While and for a our previously participants, reduction is consistent us
our to a of revenue XXXX directly Fortunately, us. to was for under is were of them. bills only and directly total about individual billed solution sent with approximately our contracts as hospitals XX% more our preferable situation XX% Medicare, Contracting with hospitals
XXXX the order. hospital for Our testing sharing prepared my our and what based patients, they values high see building with to and they you and success we performance. the plans for conclude we directly of is they of value our by them company, pay will teammates to XXXX, significant provide careers As deal for cancer a the to in clients remarks purpose further the and and our focusing with expectations initiatives a driven rewards I culture. even continue on create In are world-class develop one teamwork for factors, better clearly critical
providing We of clients. uncompromising this even more attention to our are our on also year focusing quality
Our will all training require employees. leadership initiatives for and here
to As are least automation quality process X% bar leads believe high raise test on at we lower X% that and again on once productivity. intended for focus cost, to by our the to initiatives to cost lower
growth. about our from in intend competitors satisfaction. to Our ourselves third apart to a levels of engage client is clients exceptionally further set We high of focus area in with XXXX process
are and focusing on to We legislative also reimbursement profitable growth. initiatives deliver
$X invest in million variety of to to $X long-term growth We expect a mid initiatives. to million
exciting business, for area XX% with growth clinical for consistent growth. both goals complex a our of expected Our growth testing pharma this contribution XXXX oncology our XX% to clinical in and demand revenue that increase. - mid-teens growth XX% XX% to in of pharma and business in business, with company incremental to are pharma the for financial EBITDA volume continues are generate Clearly rates for divisions wide precision on revenue the medicine our volume long-term growth our plans our
are opportunities. market-leading, confident will to to and uniquely As XXXX guidance. business. Bonello laboratory we and an review to ability the meet exciting are more full-service results that oncology-focused Bill our fourth we We floor grow growth pursuing and the remain even our Steve more positioned then to our turn to I’ll in Jones build quarter aggressively detail demand now in review
